Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca). With the approval of Lynparza and Zejula in the first-line maintenance setting, PARP inhibitors have become the new standard of care; however, these drugs provide the greatest benefit to patients with BRCA mutations or deficiencies in homologous recombination and have shown limited efficacy in patients without these genetic alterations. Availability of treatment options after disease progression is limited; the FDA’s enhanced scrutiny of PARP inhibitors led to withdrawals and label restrictions, creating further void. In addition, the optimal sequencing of therapies is not clear. A pressing unmet need remains for patients with advanced platinum-sensitive ovarian cancer.
QUESTIONS ANSWERED
- What are the key factors and goals driving medical oncologists’ prescribing decisions for advanced platinum-sensitive ovarian cancer?
- How do current therapies, such as Zejula and Lynparza, perform on key clinical attributes in this setting? Are medical oncologists satisfied with the available treatments?
- What are the most urgent unmet needs in advanced platinum-sensitive ovarian cancer? What are the most attractive opportunities for the development of novel therapies for this disease?
- What trade-offs are acceptable for U.S. and European physicians across key clinical attributes and price for a new drug for advanced platinum-sensitive ovarian cancer?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in February 2023.
Key companies: AstraZeneca, GSK, Clovis Oncology
Key drugs: Lynparza, Zejula, Rubraca, bevacizumab
Table of contents
- Ovarian Cancer - Unmet Need - Unmet Need - Advanced Platinum-Sensitive Ovarian Cancer (US/EU)
- Unmet Need - Advanced Platinum-Sensitive Ovarian Cancer - TPP Simulator - May 2023
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologists' prescribing decisions in advanced platinum-sensitive ovarian cancer
- Importance of efficacy attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: United States
- Importance of efficacy attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: Europe
- Importance of safety and tolerability attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: United States
- Importance of safety and tolerability attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: Europe
- Importance of convenience of administration attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: United States
- Importance of convenience of administration attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: Europe
- Importance of nonclinical factors to prescribing decisions in advanced platinum-sensitive ovarian cancer: United States
- Importance of nonclinical factors to prescribing decisions in advanced platinum-sensitive ovarian cancer: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in advanced platinum-sensitive ovarian cancer: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for advanced platinum-sensitive ovarian cancer: United States
- Overall performance of key therapies for advanced platinum-sensitive ovarian cancer: Europe
- Mean overall performance of key therapies for advanced platinum-sensitive ovarian cancer: United States and Europe
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select efficacy attributes: United States
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select efficacy attributes: Europe
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select safety and tolerability attributes: United States
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select safety and tolerability attributes: Europe
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select convenience of administration attributes: United States
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select convenience of administration attributes: Europe
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select nonclinical attributes: United States
- Relative performance of key therapies for advanced platinum-sensitive ovarian cancer across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in advanced platinum-sensitive ovarian cancer
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for advanced platinum-sensitive ovarian cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for advanced platinum-sensitive ovarian cancer on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in advanced platinum-sensitive ovarian cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in advanced platinum-sensitive ovarian cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in advanced platinum-sensitive ovarian cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in advanced platinum-sensitive ovarian cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in advanced platinum-sensitive ovarian cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in advanced platinum-sensitive ovarian cancer: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key nonclinical factors in advanced platinum-sensitive ovarian cancer: United States
- Surveyed medical oncologists' ascribed level of unmet need across key nonclinical factors in advanced platinum-sensitive ovarian cancer: Europe
- Key findings: unmet need in advanced platinum-sensitive ovarian cancer and related indications
- Surveyed medical oncologists' ascribed level of unmet need in advanced platinum-sensitive ovarian cancer and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in advanced platinum-sensitive ovarian cancer and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
